What Are the 3 Most Common Bloodborne Pathogens?

The three most common bloodborne pathogens are hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). These three infections dominate public health guidelines, workplace safety regulations, and screening protocols because they are transmitted through contact with infected blood and body fluids, they can cause serious long-term illness or death, and they remain widespread enough to pose a real risk in healthcare, community, and occupational settings. Each behaves differently in the body and carries a very different transmission risk per exposure, which shapes how they are prevented and treated.

Hepatitis B Virus

HBV attacks the liver. In adults who contract the virus, a majority fight off the infection on their own within a few months, but a smaller percentage develop chronic infection that can quietly damage the liver over years, leading to cirrhosis or liver cancer. In newborns and young children, the picture flips: most of those infected early in life become chronic carriers because their immature immune systems cannot mount an effective response.

What makes HBV stand out among the three pathogens is its extraordinary infectiousness. If you sustain a needlestick from a source carrying HBV, the per-exposure transmission risk is estimated at roughly 37 to 62 percent, far higher than the other two pathogens combined.¹ HBV is also remarkably hardy outside the body. Compared to other enveloped viruses like HCV, influenza, and even Ebola, HBV demonstrates the highest environmental stability, surviving on surfaces for extended periods.² That combination of high infectivity and environmental toughness is one reason HBV was historically the most feared occupational hazard for healthcare workers.

The good news is that HBV is the only one of the three for which an effective vaccine exists. Childhood vaccination programs, now standard in most countries, have dramatically reduced new infections. A study following people vaccinated with the original plasma-derived hepatitis B vaccine found evidence of lasting immune protection for at least 32 years after primary immunization, even in people whose measurable antibody levels had declined.³ That long-lasting cellular immunity, maintained by immune memory cells even when antibodies wane, is a crucial finding. However, research tracking healthcare workers and medical students vaccinated in infancy has shown that measurable protective antibody levels can decline substantially over time, with protective immunity dropping to around 28 percent by 16 to 20 years after primary vaccination.⁴ This is why healthcare workers who were vaccinated as infants are often tested for antibody levels and may need a booster before starting clinical work.

Hepatitis C Virus

HCV also targets the liver, but it takes a stealthier path. Most people who contract hepatitis C have no idea they are infected. The early symptoms, when they appear at all, tend to be vague: fatigue, mild nausea, or nothing at all. This silence is the virus’s greatest weapon. Roughly 50 to 70 percent of people with a recent HCV infection go on to develop chronic infection, defined as the virus persisting in the bloodstream for more than six months.⁵ Only about 10 to 15 percent of people who are acutely infected manage to clear the virus spontaneously.⁶

Chronic hepatitis C, left untreated, can cause progressive liver scarring over decades, eventually leading to cirrhosis, liver failure, or liver cancer. For years, HCV treatment involved long courses of interferon-based therapy with harsh side effects and modest success rates. That era is over. Modern direct-acting antiviral drugs can cure HCV in more than 95 percent of patients after just 8 to 12 weeks of treatment.⁷ These drugs work by directly interrupting the virus’s ability to replicate, and they function across essentially all HCV genotypes with few side effects.⁸

There is no vaccine for hepatitis C, which remains a major gap in prevention. Since the virus mutates rapidly and presents a moving target to the immune system, developing a vaccine has proven difficult. This means prevention still rests on avoiding blood-to-blood contact: not sharing needles or drug preparation equipment, screening the blood supply, and following standard infection-control practices in healthcare settings.

Human Immunodeficiency Virus

HIV works differently from HBV and HCV. Rather than attacking the liver, it targets a specific type of immune cell, gradually destroying the body’s ability to fight off infections.⁹ Without treatment, this process unfolds over years. The virus causes massive destruction of immune memory cells early in infection, often without obvious symptoms. The body initially compensates by regenerating these cells, which is why many people with HIV feel fine for a long time. But that regeneration is not sustainable. Over time, the immune system loses ground, and the person becomes vulnerable to infections that a healthy immune system would easily handle.¹⁰

Modern antiretroviral therapy has transformed HIV from a death sentence into a manageable chronic condition for most people who have access to treatment. People on effective therapy can maintain an undetectable viral load, which means the virus cannot be transmitted sexually. But HIV cannot be cured. The virus integrates into the host’s DNA, creating a hidden reservoir that current drugs cannot eliminate. Treatment is lifelong.

Per-exposure, HIV is actually the least infectious of the three pathogens through needlestick injuries, with a transmission risk of about 0.3 percent per exposure.¹ That relatively low per-contact risk can be misleading, though: HIV remains a massive global health burden because of the volume of exposures, the lack of a vaccine, the lifelong nature of infection, and the social factors that drive ongoing transmission.

Why Transmission Risk Per Exposure Matters

The three pathogens sit at very different points on the infectiousness scale after a single blood exposure. HBV, at 37 to 62 percent per needlestick, is in a class of its own. HCV falls in the middle at about 1.8 percent per exposure, and HIV is lowest at about 0.3 percent. These figures come from occupational exposure data and shape post-exposure protocols in hospitals.¹ If a nurse gets stuck by a contaminated needle, the response depends on which pathogen is involved: immediate hepatitis B immunoglobulin and a vaccine booster for HBV, close monitoring and early antiviral treatment for HCV, and post-exposure prophylaxis drugs for HIV.

These per-exposure figures also explain why HBV vaccination has been so transformative for healthcare. Before widespread vaccination, hepatitis B was the occupational infection healthcare workers feared most. Now, most healthcare workers in high-income countries are vaccinated, which effectively removes HBV from the equation for anyone with confirmed immunity. That leaves HCV and HIV as the primary concerns after a needlestick.

Needlestick Injuries and Occupational Risk

Needlestick and sharps injuries remain common in healthcare, particularly in resource-limited settings. A systematic review of developing countries found that roughly a third of healthcare workers reported a needlestick injury in the past year, and about two-thirds had experienced one at some point in their career.¹¹ These injuries were associated with recapping needles, heavy workloads, lack of training, and inconsistent use of protective equipment. Globally, sharps injuries are estimated to cause around 66,000 HBV infections, 16,000 HCV infections, and 200 to 5,000 HIV infections among healthcare workers each year.¹

Trends in needlestick injuries highlight the role of ongoing education. Data from a tertiary care center in South India showed that injury rates spiked when training programs were scaled back and dropped during periods of active education, with doctors experiencing the highest injury rates compared to nurses and other staff.¹² The lesson is consistent across studies: engineering controls like safety-designed needles reduce injuries, but they work best alongside regular training and a workplace culture that encourages reporting.

Transmission Beyond Healthcare Settings

While healthcare workers face the most structured occupational risk, the three bloodborne pathogens spread through several community routes as well. Sharing needles and injection equipment during drug use is the primary driver of HCV transmission in most high-income countries and a significant route for both HBV and HIV. Sexual transmission is the dominant route for HIV globally and also transmits HBV, though sexual transmission of HCV is much less efficient. Mother-to-child transmission during birth is a major concern for all three, which is why prenatal screening is standard practice.

Tattooing and body piercing carry a theoretical risk when proper infection control is not followed. A study assessing body art shops in the United States found that all shops surveyed met basic infection control standards like using sterile equipment, but fell short on administrative measures such as maintaining exposure control plans, offering hepatitis B vaccination to staff, and providing formal training on bloodborne pathogens.¹ In regulated settings, the risk from professional tattoos and piercings is very low, but informal or unregulated settings remain a concern.

Co-infection Complicates the Picture

Because these three pathogens share transmission routes, co-infection is common. A study of surgical patients at an urban university hospital found that 26 percent were HIV-positive and 35 percent had hepatitis C, with hepatitis B present in about 4 percent.¹³ Those numbers reflect a population with high-risk exposures, not the general public, but they illustrate how frequently the infections overlap.

Co-infection is not just an epidemiological curiosity; it changes how the diseases behave. People living with both HIV and HCV progress to liver cirrhosis and its complications faster than those with HCV alone.¹⁴ HIV suppresses the immune system’s ability to control HCV, allowing the liver virus to replicate more aggressively. This accelerated liver damage is one reason that screening for all three pathogens, rather than testing for one at a time, is recommended for anyone with risk factors.

How Safe Is the Blood Supply

Modern blood banking has made transfusion-transmitted infection extraordinarily rare in high-income countries. Donated blood is screened using sensitive nucleic acid testing that can detect viral genetic material before the donor’s own immune system has had time to produce antibodies. The detection windows for these tests are remarkably short: about 5 days for HIV, roughly 3 days for HCV, and around 17 days for HBV.¹⁵ The HBV window is the longest, which reflects both the virus’s slower replication kinetics early in infection and its ability to circulate at low levels.

In practice, the residual risk of receiving a transfusion-transmitted infection is vanishingly small. Estimates from Australia calculated the risk at roughly 1 in 7.3 million for HIV, 1 in 3.6 million for HCV, and 1 in 1.3 million for HBV.¹⁶ HBV carries the highest residual risk of the three, consistent with its longer detection window and higher environmental stability. These numbers continue to improve as testing technology advances.

Prevention Beyond Vaccination

Because only HBV has a vaccine, preventing HCV and HIV requires different strategies. For HIV, pre-exposure prophylaxis, or PrEP, has become a powerful tool. A systematic review of randomized trials found that oral PrEP reduced HIV infection risk by about half overall compared to placebo, with much higher effectiveness in people who took the medication consistently.¹⁷ Adherence turns out to be the critical variable. Real-world data from France showed PrEP effectiveness of 93 percent among high-consumption users, dropping to just 18 percent among those who took it inconsistently.¹⁸ A newer option, long-acting injectable cabotegravir given every two months, has proven even more effective in clinical trials, reducing risk by up to 89 percent compared to daily oral PrEP and sidestepping the adherence problem entirely.¹⁹

For people who inject drugs, harm reduction programs have demonstrable effects on all three pathogens. Needle and syringe exchange programs are associated with a 10 to 40 percent reduction in HIV and HCV transmission, while opioid agonist therapy like methadone or buprenorphine is linked to a 50 to 60 percent reduction, with even larger effects when the two approaches are combined.²⁰ Sharing of injection paraphernalia also drops substantially in programs that provide clean equipment and treatment for substance use disorders.

Stigma as a Barrier to Testing

Effective prevention and treatment tools exist for all three pathogens, but they only work when people know their status. Stigma remains one of the biggest obstacles to testing, particularly for HIV. Research among foreign-born Black men from the Caribbean in the United States identified multiple overlapping barriers: anticipated stigma about a positive result, low perception of personal risk, distrust of medical and government institutions, and fear of being identified publicly.²¹ Similar patterns show up in very different populations. A qualitative synthesis examining men who have sex with men and transgender women in sub-Saharan Africa found that criminalization of same-sex relationships, physical and sexual violence, and lack of tailored services drove people away from testing entirely.²² In some cases, people responded by avoiding testing, hiding their status, or turning to informal testing sources with no connection to care.

Among gay and bisexual migrants in Australia, stigma around both HIV status and sexual identity created compounding barriers, including reluctance to access prevention tools like PrEP, fear of visa consequences from a positive test result, and difficulty navigating an unfamiliar healthcare system.²³ While most of this stigma research focuses on HIV, the dynamics apply to hepatitis testing as well, particularly for HCV among people who inject drugs, where the association between infection and drug use creates its own layer of shame and avoidance. The paradox is consistent across settings: the populations with the highest need for testing are often the hardest to reach, not because of a lack of available tests, but because of social and structural forces that make getting tested feel dangerous.